Therapy Optimization in Multiple Sclerosis (MS)

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Neuroscience, Inc.
• Treatments: (T,G)-A-L; Glatiramer Acetate; Interferon beta-1b; Interferon-beta

Criteria

Inclusion Criteria:

• Male or female, 18 years of age or older, with a diagnosis of MS.

• Being treated with Glatiramer Acetate (GA) or (IFN)-β

• Receiving therapy from a participating Specialty Pharmacy

Exclusion Criteria:

• Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study

• Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)

• Unlikely to be able to participate for the full two years of the study